IP Library Granted Patent US 9,464,286
Granted Patent B2
US 9,464,286 · App. 11/480,037 · Granted Oct 11, 2016

High throughput generation and affinity maturation of humanized antibody

Inventors: Li Zhu (Palo Alto, CA); Shuanghong Wei (San Jose, CA); Shaobing B. Hua (Cupertino, CA)
Assignee: Adimab, LLC
C12N15/1041C12N15/1062C12N15/1086
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,464,286
App. No.
11/480,037
Granted
Oct 11, 2016
Kind
B2
Abstract

Compositions, methods, and kits are provided for efficiently generating and screening humanized antibody with high affinity against a specific antigen. The library of humanized antibody is generated by mutagenizing a chimeric antibody template that combines human antibody framework and antigen binding sites of a non-human antibody. Alternatively, the library of humanized antibody is generated by grafting essential antigen-recognition segment(s) such as CDRs of the non-human antibody into the corresponding position(s) of each member of a human antibody library. This library of humanized antibody is then screened for high affinity binding toward a specific antigen in vivo in organism such as yeast or in vitro using techniques such as ribosome display or mRNA display. The overall process can be efficiently performed in a high throughput and automated manner, thus mimicking the natural process of antibody affinity maturation.

Claims (42)

1. A method for screening a library of human or humanized antibodies in yeast, comprising:

assembling a library of antibodies in yeast cells, wherein the step of assembling the library comprises:

mutagenizing a V H and V L to produce a plurality of V H and V L ; and

introducing the plurality of V H and V L into expression vectors by homologous recombination;

expressing the library of human or humanized antibodies in the yeast cells, wherein each of the human or humanized antibodies comprises a V H and a V L which form a V H /V L heterodimer in the yeast cells;

contacting a specific target protein with the library of human or humanized antibodies expressed in the yeast cells; and

selecting those human or humanized antibodies based on their binding to the target protein.

2. The method of claim 1 , wherein a member of the library of humanized antibodies comprises:

V H having 3 CDRs, wherein at least one of the CDRs is a CDR3 of a non-human V H grafted into a human antibody framework, and

V L having 3 CDRs, wherein at least one of the CDRs is a CDR3 of a non-human V L grafted into a human antibody framework; wherein

the one or more heavy chain CDR or CDRs and the one or more light chain CDR or CDRs are from the same non-human antibody, and the selected antibodies bind to the same target protein as the antibody from which the non-human CDRs are obtained.

3. The method of claim 1 , wherein the library of humanized antibodies is generated by mutagenizing a chimeric antibody that comprises:

V H having 3 CDRs, wherein at least one of the CDRs is a CDR3 of a non-human V H grafted into a human antibody framework, and

V L having 3 CDRs, wherein at least one of the CDRs is a CDR3 of a non-human V L grafted into a human antibody framework, wherein

the one or more heavy chain CDR or CDRs and the one or more light chain CDR or CDRs are from the same non-human antibody, and the selected antibodies bind to the same target protein as the antibody from which the non-human CDRs are obtained.

4. The method of claim 1 , wherein the V H and the VL each is linked with a zipper domain by which the V H and-the V L are associated with each other to form a heterodimer.

5. The method of claim 4 , wherein the zipper domains of the V H and the V L facilitate the heterodimerization of the V H and the V L through coiled-coil interactions.

6. The method of claim 4 , wherein the zipper domains of the V H and the V L are leucine zippers.

7. The method of claim 4 , wherein the zipper domains of the V H and the V L are leucine zippers formed by the leucine zippers from Fos and Jun.

8. The method of claim 4 , wherein the zipper domains of the V H and the V L are leucine zippers formed by the leucine zippers from Myc and Max.

9. The method of claim 4 , wherein the zipper domains of the V H and the V L each is linked to the C-terminus of the V H and the V L , respectively.

10. A method for screening a library of human or humanized antibodies in yeast, comprising:

assembling a library of antibodies in yeast cells, wherein the step of assembling the library comprises:

mutagenizing a V H and V L to produce a plurality of V H and V L ; and

introducing the plurality of V H and V L into expression vectors by gap repair homologous recombination;

expressing the library of human or humanized antibodies in the yeast cells, wherein each of the human or humanized antibodies comprises a V H and a V L which form a V H /V L heterodimer in the yeast cells;

contacting a specific target protein with the library of human or humanized antibodies expressed in the yeast cells; and

selecting those human or humanized antibodies based on their binding to the target protein.

11. The method of claim 10 , wherein a member of the library of humanized antibodies comprises:

V H having 3 CDRs, wherein at least one of the CDRs is a CDR3 of a non-human V H grafted into a human antibody framework, and

V L having 3 CDRs, wherein at least one of the CDRs is a CDR3 of a non-human V L grafted into a human antibody framework; wherein

the one or more heavy chain CDR or CDRs and the one or more light chain CDR or CDRs are from the same non-human antibody, and the selected antibodies bind to the same target protein as the antibody from which the non-human CDRs are obtained.

12. The method of claim 10 , wherein the library of humanized antibodies is generated by mutagenizing a chimeric antibody that comprises:

V H having 3 CDRs, wherein at least one of the CDRs is a CDR3 of a non-human V H grafted into a human antibody framework, and

V L having 3 CDRs, wherein at least one of the CDRs is a CDR3 of a non-human V L grafted into a human antibody framework, wherein

the one or more heavy chain CDR or CDRs and the one or more light chain CDR or CDRs are from the same non-human antibody, and the selected antibodies bind to the same target protein as the antibody from which the non-human CDRs are obtained.

13. The method of claim 10 , wherein the V H and the VL each is linked with a zipper domain by which the V H and-the V L are associated with each other to form a heterodimer.

14. The method of claim 13 , wherein the zipper domains of the V H and the V L facilitate the heterodimerization of the V H and the V L through coiled-coil interactions.

15. The method of claim 13 , wherein the zipper domains of the V H and the V L are leucine zippers.

16. The method of claim 13 , wherein the zipper domains of the V H and the V L are leucine zippers formed by the leucine zippers from Fos and Jun.

17. The method of claim 13 , wherein the zipper domains of the V H and the V L are leucine zippers formed by the leucine zippers from Myc and Max.

18. The method of claim 13 , wherein the zipper domains of the V H and the V L each is linked to the C-terminus of the V H and the V L , respectively.

Assignments (3)
MERGER Recorded May 16, 2011
From: ADIMAB, INC.
To: ADIMAB, LLC
Reel/Frame 026286/0571 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 11, 2007
From: GENETASTIX, INC.
To: ADIMAB, INC.
Reel/Frame 019541/0170 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 7, 2006
From: ZHU, LI; WEI, SHUANGHONG; HUA, SHAOBING B.
To: GENETASTIX CORPORATION
Reel/Frame 018065/0989 →
Continuity (3)
Continuation 10460595 · Jun 11, 2003
Provisional Application 60403296 · Aug 12, 2002
Related Publication 20060246515A1 · Nov 2, 2006